Biogen

The Global Gastrointestinal Diseases Therapeutics Market is projected to grow by USD 18.5 billion from 2024-2028, driven by increasing disease incidence and nutritional therapies. Key players include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, and others. High treatment costs pose a challenge.

New SMA best practice recommendations emphasize efficient coordination between caregivers, primary care practitioners, and referral centers for rapid diagnosis and early treatment initiation. Differences in treatment approval processes between the US and Spain highlight the need for collaboration between healthcare providers and families to optimize SMA patient outcomes.

The life sciences industry faces efficiency challenges driven by legislative changes and funding crunches, prompting a shift towards innovative, differentiated products. Outsourcing and tech-enabled solutions are crucial for biotechs and pharma companies to maximize value and speed up drug commercialization. Embracing AI and data analytics can revolutionize research and clinical trials, addressing data challenges and enhancing efficiency.

AstraZeneca to pay $2B to CSPC for a cardiovascular drug, Astellas Pharma licenses gene therapy from AviadoBio, Merck partners with Mestag Therapeutics for fibrosis treatments, Insitro signs three agreements with Eli Lilly for metabolic diseases, MiNK Therapeutics and Autonomous Therapeutics collaborate on metastatic tumors, Bayer and MOMA Therapeutics partner in oncology, Wonderskin names 5W Public Relations as AOR, Eversana signs with Oracle Argus Cloud, Qinotto and Eli Lilly collaborate, Onspire Health acquires Aesthetic Brand Marketing, Reunion Neuroscience partners with Seleni Institute, Danco Laboratories to seek FDA approval for Mifeprex use in miscarriages, Exact Sciences' Cologuard Plus wins FDA approval, Boehringer Ingelheim's survodutide gets Breakthrough Therapy designation, Lunds & Byerlys recalls Lone Star Dip, Kezar Life Sciences' zetomipzomib development halted by FDA, Bayer's elinzanetant NDA accepted by FDA, Biogen's felzartamab gets Breakthrough Therapy Designation, Black Diamond Therapeutics to cut jobs, Upstream Bio targets $182M for IPO, City Therapeutics launches with $135M, Purespring Therapeutics raises $105M, Judo Bio launches with $100M, Orasis Pharmaceuticals raises $78M, CAMP4 Therapeutics targets $67M for IPO, Basecamp Research closes $60M Series B, Arda Therapeutics raises $43M Series A, Crinetics Pharmaceuticals announces public offering, GSK to pay $2.2B to settle Zantac lawsuits, Scholar Rock's SMA drug shows muscle function improvement, CDC to screen travelers due to Marburg virus outbreak in Rwanda, Ad Council, AMA, and CDC launch flu vaccination campaign, Sage Therapeutics' Sage-718 fails in Alzheimer's study, WeightWatchers adds GLP-1 obesity treatments, Gritstone Bio files for Chapter 11, BioPharmCatalyst launches AI-powered chatbot Aiden, Otsuka Precision Health and Amalgam Rx launch Alzheimer's app Elevmi, PatientPoint unveils interactive communication solution, Curia rebrands, Switzerland's COMCO terminates Novartis investigation, Bluebird Bio's Skysona linked to blood cancer in seven children, Solera Health rebrands, HearingLife launches pickleball sweepstakes, Alfasigma launches Morpho brand, Healthy Minds Innovations launches Our World Of Emotions campaign.

FDA grants Biogen's monoclonal antibody felzartamab breakthrough therapy designation for treating late antibody-mediated rejection in kidney transplant patients, based on positive Phase II trial data. Biogen plans to initiate Phase III trials for felzartamab in multiple indications next year. The therapy, acquired through the $1.15bn HI-Bio acquisition, is expected to generate over $776m by 2032 if approved.

The FDA granted Breakthrough Therapy Designation to Biogen’s felzartamab for treating late antibody-mediated rejection (AMR) in kidney transplant recipients. A Phase II trial showed 82% AMR resolution in the felzartamab group vs. 20% in the placebo group, with acceptable safety and efficacy profiles. Felzartamab previously received BTD and Orphan Drug Designation for primary membranous nephropathy and AMR.

Cassava Sciences proceeds with Phase III trials after settling a $40m SEC case alleging misleading data from its Phase IIb Alzheimer’s drug trial. The SEC charged Cassava, its former executives, and a consultant for manipulating trial results. Cassava paid $40m without admitting or denying the allegations, while former executives and the consultant also settled with penalties. The company faces challenges in securing FDA approval amid ongoing controversies and potential fraudulent data.

Biogen's felzartamab receives U.S. FDA Breakthrough Therapy Designation for treating antibody-mediated rejection in kidney transplant patients, highlighting unmet medical needs and planned Phase 3 trials for 2025.

Purespring Therapeutics secures £80m ($105m) to advance its AAV gene therapy PS-002 for IgA nephropathy (IgAN) into Phase I/II trials. The therapy targets podocytes, crucial for kidney function, aiming to address inflammation and prevent end-stage renal disease. The funding round was led by Sofinnova Partners and includes Gilde Healthcare, Forbion, British Patient Capital, and Syncona. Purespring's platform, FunSel, selects effective treatments from a library of AAV vectors, independent of specific genes or mechanisms.

Scholar Rock's experimental drug apitegromab, designed to block myostatin activation, showed significant muscle function improvement in SMA patients in a Phase 3 study, leading to a $300 million stock offering. The company plans FDA and EMA submissions for 2025 commercial launch, and is exploring apitegromab's use in preserving muscle mass during weight loss treatment.